we conducted a randomized multicenter trial comparing low-dose cytarabine ( ld ara-c ) ( 20 mg/m2 for 21 days ) with an intensive chemotherapy ( rubidazone [ a daunorubicin-derived agent ] , 100 mg/m2 for 4 days , ara-c 200 mg/m2 for 7 days ) in 87 patients over 65 years of age with de novo acute nonlymphocytic leukemia ( anll ) .
C0011015
daunorubicin
C0023467
acute nonlymphocytic leukemia